Research Article
No access
Published Online: 29 June 2009

Remuscularizing Failing Hearts with Tissue Engineered Myocardium

Publication: Antioxidants & Redox Signaling
Volume 11, Issue Number 8

Abstract

Supporting or even replacing diseased myocardium with in vitro engineered heart muscle may become a viable option for patients with heart failure. The key to success will be to (1) generate human heart muscle equivalents in vitro, (2) integrate the latter into a failing heart, (3) ensure long-term functional competence of the grafts, and (4) prevent unwanted effects including arrhythmias, inflammation/rejection, and tumor formation. Several promising tissue engineering technologies have already been developed and are presently being tested in animal models. The rapidly evolving field of human stem cell biology has in parallel identified unique cell sources of potential clinical relevance. Somatic cell reprogramming and nontransduced, nonembryonic pluripotent stem cells may be of particular interest to eventually provide patient-specific cells and tissues. Yet, limited cardiac differentiation and cell immaturity still restrict a broad application of any stem cell type in cardiac muscle engineering. Bioreactor technologies, transgenic “optimization,” and growth factor, as well as physical conditioning, have been used to address these caveats. This review summarizes different tissue engineering modalities, speculates on potential clinical uses, provides an overview on cell sources that may ultimately facilitate a patient-specific application, and discusses limitations of tissue engineering-based myocardial repair. Antioxid. Redox Signal. 11, 2011–2023.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

cover image Antioxidants & Redox Signaling
Antioxidants & Redox Signaling
Volume 11Issue Number 8August 2009
Pages: 2011 - 2023
PubMed: 19203222

History

Published in print: August 2009
Published online: 29 June 2009
Published ahead of print: 27 April 2009
Published ahead of production: 9 February 2009
Accepted: 7 February 2009
Received: 20 January 2009

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Wolfram–Hubertus Zimmermann
Department of Pharmacology, Georg-August University Goettingen, Goettingen, Germany.
Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg-Eppendorf, Hamburg Germany.

Notes

Address correspondence to:
Wolfram–Hubertus Zimmermann, M.D.
Georg–August University Goettingen
Department of Pharmacology
Robert-Koch-Str. 40
37075 Goettingen,
Germany
E-mail: [email protected]

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top